Inventory Turnover measures how fast the company turns over its inventory within a year.
Tissue Regenix Group's Inventory Turnover for the
six
months ended in Jun. 2025 was 0.50.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tissue Regenix Group's Inventory-to-Revenue for the
six
months ended in Jun. 2025 was 1.16.
Tissue Regenix Group (FRA:LSW) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Tissue Regenix Group's Inventory Turnover for the
six
months ended in Jun. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tissue Regenix Group's Inventory to Revenue for the
six
months ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Tissue Regenix Group Days Inventory Related Terms
Tissue Regenix Group Days Inventory Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Days Inventory of 365.25 as of Jun. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Tissue Regenix Group and its competitors. This is 29% above median its historical median of 283.50. Over the past decade, Tissue Regenix Group's Days Inventory has ranged from 116.22 to 382.38.
Is Tissue Regenix Group's Days Inventory too high?
Tissue Regenix Group's current Days Inventory of 365.25 is 29% above median its 10-year median of 283.50. Over the past 10 years, this metric has ranged from a low of 116.22 to a high of 382.38. The Biotechnology industry median Days Inventory is 183.88. Tissue Regenix Group's value of 365.25 is 98.6% above this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Days Inventory compare to VRTX and REGN?
Tissue Regenix Group's Days Inventory of 365.25 can be compared against companies in the Biotechnology industry. The industry median Days Inventory is 183.88. Tissue Regenix Group's value of 365.25 is 98.6% above this benchmark. Historically, Tissue Regenix Group's own Days Inventory has ranged from 116.22 to 382.38 over the past decade. While the company's 10-year median is 283.50 vs. the industry median of 183.88, Tissue Regenix Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Days Inventory of 365.25 is 98.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Days Inventory is 365.25, which is 29% above median its own 10-year median of 283.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Days Inventory of 365.25. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Days Inventory is 365.25, which is 29% above median its 10-year median of 283.50 and 98.6% above the Biotechnology industry median of 183.88. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Days Inventory is 365.25 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Days Inventory: 365.25 (29% above median its 10-year median of 283.50)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 98.6% above the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
